Bioventus Inc. (BVS)

US — Healthcare Sector
Peers: TIVC  TLIS  BJDX  HSCS  NUWE  BBLG  NAOV  VVOS  RPID 

Automate Your Wheel Strategy on BVS

With Tiblio's Option Bot, you can configure your own wheel strategy including BVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BVS
  • Rev/Share 8.6004
  • Book/Share 2.8099
  • PB 2.8695
  • Debt/Equity 2.3351
  • CurrentRatio 1.427
  • ROIC -0.0195

 

  • MktCap 427342944.0
  • FreeCF/Share 0.3625
  • PFCF 17.8595
  • PE -13.4486
  • Debt/Assets 0.5003
  • DivYield 0
  • ROE -0.2122

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade BVS JP Morgan Underweight Neutral $12 $13 Dec. 17, 2024

News

Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript
BVS
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Bioventus Inc. (NASDAQ:BVS ) Q1 2025 Results Conference Call May 6, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Robbie Marcus - JPMorgan Operator Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.

Read More
image for news Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates
BVS
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Bioventus (BVS) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.

Read More
image for news Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates
Bioventus Reports First Quarter Financial Results
BVS
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

DURHAM, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 29, 2025.

Read More
image for news Bioventus Reports First Quarter Financial Results
Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
BVS
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral

DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025.

Read More
image for news Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
BVS, ENSG, FOLD, RIGL
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.

Read More
image for news 4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now
BVS
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive

Bioventus (BVS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Read More
image for news Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know
BVS
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive

Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Bioventus (BVS) Upgraded to Buy: Here's What You Should Know
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript
BVS
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral

Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Read More
image for news Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
BVS
Published: March 11, 2025 by: Benzinga
Sentiment: Positive

On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.

Read More
image for news Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates
BVS
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive

Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

Read More
image for news Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates

About Bioventus Inc. (BVS)

  • IPO Date 2021-02-11
  • Website https://www.bioventus.com
  • Industry Medical - Devices
  • CEO Mr. Robert E. Claypoole
  • Employees 930

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.